摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4Z)-4-(1,2-oxazol-3-ylidene)-12-oxa-3,5,8-triazatricyclo[7.4.0.02,6]trideca-1(9),2,5,7-tetraene;phosphoric acid

中文名称
——
中文别名
——
英文名称
(4Z)-4-(1,2-oxazol-3-ylidene)-12-oxa-3,5,8-triazatricyclo[7.4.0.02,6]trideca-1(9),2,5,7-tetraene;phosphoric acid
英文别名
——
(4Z)-4-(1,2-oxazol-3-ylidene)-12-oxa-3,5,8-triazatricyclo[7.4.0.02,6]trideca-1(9),2,5,7-tetraene;phosphoric acid化学式
CAS
——
化学式
C12H13N4O6P
mdl
——
分子量
340.23
InChiKey
CAKJTDWTGCLYDZ-NBYYMMLRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.3
  • 重原子数:
    23
  • 可旋转键数:
    0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    145
  • 氢给体数:
    4
  • 氢受体数:
    10

文献信息

  • [EN] ARYL IMIDAZOLE COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS<br/>[FR] COMPOSÉ ARYLIMIDAZOLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PRODUCTION DE LA PROTÉINE AMYLOÏDE BÊTA
    申请人:EISAI R&D MAN CO LTD
    公开号:WO2010098488A1
    公开(公告)日:2010-09-02
    A compound represented by the formula (I): or a pharmacologically acceptable salt or ester thereof, wherein Ring A represents a triazolyl group or the like which may be substituted, Ring B represents a phenyl group or the like which may be substituted, X1 represents a single bond or the like, R1 and R2 each represent a C1-6 alkyl group or the like, m represents an integer of 0 to 3, and n represents an integer of 0 to 2, is effective as a therapeutic agent for a disease caused by Aβ.
    一种由化学式(I)表示的化合物,或其药理学上可接受的盐或酯,其中环A代表可能被取代的三唑基团或类似物,环B代表可能被取代的苯基团或类似物,X1代表单键或类似物,R1和R2分别代表C1-6烷基或类似物,m代表0到3的整数,n代表0到2的整数,对于由Aβ引起的疾病具有治疗作用。
  • MULTI-CYCLIC COMPOUNDS
    申请人:KIMURA Teiji
    公开号:US20090062529A1
    公开(公告)日:2009-03-05
    A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar 1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar 2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X 1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.
    一种由化学式(I)表示的化合物或其药理学可接受的盐,其中Ar1代表可用C1-6烷基基团取代的咪唑基团或类似基团,Ar2代表可用C1-6烷氧基团取代的苯基团或类似基团,X1代表双键或类似基团,Het代表可用C1-6烷基基团或类似基团取代的三唑基团或类似基团,对由Aβ引起的疾病具有治疗或预防作用。
  • [EN] NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS CONTENANT DE L'AZOTE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PRODUCTION DE LA BÊTA-AMYLOÏDE
    申请人:EISAI R&D MAN CO LTD
    公开号:WO2010098487A1
    公开(公告)日:2010-09-02
    A compound represented by the formula [I]: or a pharmacologically acceptable salt or ester thereof, wherein Ring A represents a five-membered aromatic heterocyclic group or the like fused with a non-aromatic ring group, which may be substituted, Ring B represents a phenyl group or the like which may be substituted, X1 represents a single bond or the like, R1 and R2 each represent a C1-6 alkyl group or the like, m represents an integer of 0 to 3, and n represents an integer of 0 to 2, is effective as a therapeutic agent for a disease caused by Aβ.
    化合物的分子式为[I]:或其药理学可接受的盐或酯,其中环A代表一个五元芳香杂环基团或类似于非芳香环基团的融合物,可以被取代,环B代表一个苯基或类似的基团,可以被取代,X1代表一个单键或类似物,R1和R2分别代表一个C1-6烷基基团或类似物,m表示0到3的整数,n表示0到2的整数,对由Aβ引起的疾病具有治疗作用。
  • [EN] IMIDAZOLYLPYRAZINE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOLYLPYRAZINE
    申请人:EISAI R&D MAN CO LTD
    公开号:WO2010098495A1
    公开(公告)日:2010-09-02
    To provide a novel low-molecular-weight compound that inhibits the production of amyloid-β (Aβ ). A compound represented by the formula [I]: or a pharmacologically acceptable salt or ester thereof, wherein R1 and R2 are the same or different and each represent a substituent selected from the following Substituent Group a1; m represents an integer of 0 to 3; n represents an integer of 0 to 2; X1 represents a single bond or the like; X2 represents a single bond or the like; Ring A represents a five-membered aromatic heterocyclic group or the like which contains two or more nitrogen atoms and may have 1 to 3 substituents selected from the following Substituent Group b1; and Ring B represents a monocyclic or fused cyclic aromatic ring group such as the formula [2] which may have 1 to 3 substituents selected from the following Substituent Group c1, is effective as a therapeutic agent for a disease such as Alzheimer's disease. Substituent Group a1: a C1-6 alkyl group and the like Substituent Group b1: a C1-6 alkyl group and the like Substituent Group c1: an amino group and the like
    提供一种新型低分子量化合物,该化合物能够抑制淀粉样蛋白-β(Aβ)的产生。表示为化学式[I]的化合物,或其药理学上可接受的盐或酯,其中R1和R2相同或不同,每个代表以下取代基团a1中选择的取代基;m代表0到3的整数;n代表0到2的整数;X1代表单键或类似物;X2代表单键或类似物;环A代表含有两个或更多氮原子并且可能具有1到3个取代基团b1中选择的取代基的五元芳香杂环基团或类似物;环B代表可能具有1到3个取代基团c1中选择的取代基的单环或融合环芳香环基团,如化学式[2]所示,对于阿尔茨海默病等疾病具有治疗作用。取代基团a1:C1-6烷基基团等;取代基团b1:C1-6烷基基团等;取代基团c1:氨基团等。
  • Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors
    申请人:Kitazawa Noritaka
    公开号:US20120053171A1
    公开(公告)日:2012-03-01
    A compound represented by the formula [I]: or a pharmacologically acceptable salt or ester thereof, wherein Ring A represents a five-membered aromatic heterocyclic group or the like fused with a non-aromatic ring group, which may be substituted, Ring B represents a phenyl group or the like which may be substituted, X1 represents a single bond or the like, R1 and R2 each represent a C1-6 alkyl group or the like, m represents an integer of 0 to 3, and n represents an integer of 0 to 2, is effective as a therapeutic agent for a disease caused by Aβ.
    化合物的化学式为[I],或其药理学上可接受的盐或酯,其中环A代表一个五元芳香杂环基团或类似物,与非芳香环基团融合,可以被取代,环B代表苯基或类似物,可以被取代,X1代表单键或类似物,R1和R2各代表C1-6烷基或类似物,m代表0至3的整数,n代表0至2的整数,该化合物对由Aβ引起的疾病具有治疗作用。
查看更多

同类化合物

龙胆胺 龙胆定碱 西藏龙胆碱 萤光红BK 苯酰胺,N-(1,5,7,8-四氢-4-羰基-4H-吡喃并[4,3-b]吡啶-3-基)- 秦艽碱丙 秦艽甲素 盐酸伊立替康杂质20 溶剂红197 伊立替康杂质29 α.-D-核-七吡喃糖苷-6-酮糖,甲基3,7-二脱氧-2-O-甲基-4-O-(苯基甲基)- N-(3,4-二氢-2H-吡喃并[3,2-b]吡啶-4-基)-n-甲基甘氨酸 N-(2-(4-甲氧苯基)乙烯基)-吡咯烷-2,5-二酮 8-碘-3,4-二氢-2H-吡喃并[3,2-c]吡啶 7H-噻喃并[2,3-d]嘧啶 7-溴-2H-吡喃并[3,2-b]吡啶 7-氯-3,4-二氢-2H-吡喃并[2,3-B]吡啶 7-乙基-10-羟基喜树碱中间体 7,8-二氢-6H-硫代吡喃并[3,2-d]嘧啶-2,4-二醇 7,8-二氢-5H-吡喃并[4,3-b]吡啶-3-胺 7,8-二氢-2-(甲硫基)-3H-噻喃并[3,2-d]嘧啶-4(6H)-酮 6H-噻喃并[3,2-d]嘧啶 6-碘-3,4-二氢-2h-吡喃并[3,2-b]吡啶-8-甲醛 6-甲基-3,4-二氢吡喃并[4,3-d]吡啶-1-酮 6-溴-2-苯基-2H-吡喃并[2,3-b]吡啶 6-溴-2-(4-甲基苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-溴-2-(3,4-二氯苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-氯-2-(4-氯苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-氯-2-(3,4-二氯苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)-3,4-二氢-2H-吡喃[2,3-b]吡啶 6,8-二碘-3,4-二氢-2H-吡喃[3,2-b]吡啶 5H-噻喃并[2,3-d]嘧啶 5-氧杂-10-氮杂三环[6.2.1.04,9]十一碳-1,3,7,9-四烯 5,8-二氢-6H-吡喃并[3,4-b]吡啶 4H-吡喃并[2,3-b]吡啶-4-酮,6-氯-2,3-二氢-2-甲基-,(R)- 4H-吡喃并[2,3-b]吡啶-4-酮 4-羟甲基-3,4-二氢-2H-吡喃[3,2-B]吡啶-4-醇 4-甲基-7-吗啉基-2H-吡喃并[2,3-b]吡啶-2-酮 4-乙基-7,8-二氢-4-羟基-1H-吡喃并[3,4-f]吲嗪-3,6,10(4H)-三酮 4,4',5'-三甲基氮杂补骨脂素 4'-乙基-7',8'-二氢-螺[1,3-二氧戊环-2,6'(3'H)-[1H]吡喃并[3,4-f]吲哚嗪]-3',10'(4′H)-二酮-d5 4'-乙基-7',8'-二氢-4'-羟基-螺[1,3-二氧戊环-2,6'(3'H)-[1H]吡喃并[3,4-f]吲哚嗪]-3′,10′(4′H)-二酮-d5 3-异噻唑甲酰胺,N-(4-氯-7,8-二氢-5H-吡喃并[4,3-b]吡啶-3-基)- 3-(二烯丙基氨基)-7-氧代-7H-苯并吡喃并[3',2':3,4]吡啶并[1,2-a]苯并咪唑-6-甲腈 3-(4-羟苯在)-4H-吡喃[2,3-B]吡啶-4-酮 3,4-二氢-4-亚甲基-(9ci)-2H-吡喃并[3,2-b]吡啶 3,4-二氢-2h-吡喃并[3,2-b]吡啶-8-羧酸 3,4-二氢-2H-吡喃并[3,2-c]吡啶 3,4-二氢-2H-吡喃并[3,2-b]吡啶-3-基甲醇 3,4-二氢-2H-吡喃并[3,2-b]吡啶-2-醇